MaxCyte, Inc. Publication of Annual Report and Accounts (0186C)

TIDMMXCT TIDMTTM

RNS Number : 0186C

MaxCyte, Inc.

16 June 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

Publication of Annual Report and Accounts

Gaithersburg, Maryland - 16 June 2021: MaxCyte (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announces that it has published its Annual Report and Accounts for the year ending 31 December 2020.

The Annual Report is available to view on the Company's website at https://investors.maxcyte.com/news-events/documents-presentations and printed copies of the reports have been posted to those shareholders who have elected to continue to receive paper communications.

###

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialisation. MaxCyte's existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centres focused on translational research. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted pre-clinical and clinical licences to academic and industry customers covering over an estimated 140 programmes, of which an estimated 100 programmes are for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

For further information please contact:

 
 MaxCyte Inc. 
  Doug Doerfler, Chief Executive Officer 
  Amanda Murphy, Chief Financial Officer    +1 301 944 1660 
 
   Nominated Adviser and Joint Corporate 
   Broker 
   Panmure Gordon 
   Emma Earl 
   Freddy Crossley 
   Corporate Broking 
   Rupert Dearden                             +44 (0)20 7886 2500 
 
   Joint Corporate Broker 
   Numis Securities Limited 
   James Black 
   Duncan Monteith                            +44 (0)20 7260 1000 
 Joint Corporate Broker 
  Stifel Nicolaus Europe Limited 
  Healthcare Investment Banking 
  Nicholas Moore / Ben Maddison / 
  Samira Essebiyea 
  Corporate Broking 
  Nick Adams                                +44 (0) 20 7710 7600 
 
   Financial PR Adviser                       +44 (0)203 709 5700 
   Consilium Strategic Communications         maxcyte@consilium-comms.com 
   Mary-Jane Elliott / Chris Welsh

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACSFFFLLRSIELIL

(END) Dow Jones Newswires

June 16, 2021 02:01 ET (06:01 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024